| 2023 ATS Final Program | 1 |
| Cover | 1 |
| ATS 2023 International Conference Planners Disclosures | 3 |
| Welcome to ATS 2023 | 5 |
| Contents | 7 |
| Program at a Glance | 9 |
| General Information | 10 |
| The Exhibit Hall | 12 |
| Industry Programs | 13 |
| Networking Opportunities at ATS 2023 | 15 |
| International Scholars Poster Colloquium | 17 |
| General Sessions/ Awards | 18 |
| ATS 2023 Sessions | 19 |
| Conference Sessions | 20 |
| FRIDAY • MAY 19 | 21 |
| PG1A CRITICAL CARE ULTRASOUND AND ECHOCARDIOGRAPHY I | 21 |
| PG2 BRONCH DAY 2023: A COMPREHENSIVE, HANDS-ON GUIDE TO BASIC BRONCHOSCOPY, EBUS, AND NAVIGATIONAL BRONCHOSCOPY | 22 |
| PG3 PEDIATRIC SLEEP-RELATED BREATHING DISORDERS: STATE OF THE ART AND BEST PRACTICES | 23 |
| PG4 STATE OF THE ART MANAGEMENT OF NONINVASIVE VENTILATION FROM HOSPITAL TO AMBULATORY CARE | 24 |
| SATURDAY • MAY 20 | 26 |
| PG1B CRITICAL CARE ULTRASOUND AND ECHOCARDIOGRAPHY II | 26 |
| PG5 SEVERE ASTHMA 2023: IMPLEMENTINGCURRENT GUIDELINES INTO PRACTICE | 27 |
| PG6 TOWARDS DISMANTLING STRUCTURAL INJUSTICE IN PULMONARY AND CRITICAL CARE MEDICINE - A PRIMER ON HEALTH EQUITY RESEARCH | 28 |
| PG7 UPDATES ON LUNG TRANSPLANTATION; WHAT PULMONOLOGISTS NEED TO KNOW | 28 |
| PG8 INTERSTITIAL LUNG DISEASE: DELIVERING OPTIMAL, PATIENT CENTERED CARE | 29 |
| PG9 FUND ME: OVERCOMING THE BARRIERS AND CHALLENGES TO SUCCESSFUL CAREER DEVELOPMENT AWARDS | 30 |
| PG10 QUITTING IS WINNING: TOBACCO AND E-CIGARETTE CESSATION | 31 |
| PG11 A HANDS-ON INTRODUCTION TO STUDYING THE LUNG MICROBIOME | 32 |
| PG12 MOLECULAR TARGETING IN COPD - FROM BASICS THROUGH MULTI-OMIC INTEGRATION TO NOVEL THERAPEUTICS | 33 |
| PG13 HUFFING AND PUFFING: BEST PRACTICE AND STATE OF THE ART IN CPET AND PFT | 34 |
| PG14 STATE OF THE ART: LUNG CANCER IN 2023 | 35 |
| PG15 TEACHING SKILLS FOR BUSY CLINICIANS: EFFICIENT AND EFFECTIVE TEACHING STRATEGIES FOR ALL CLINICIANS | 36 |
| NETWORKING SUPER CENTER | 37 |
| OPENING CEREMONY | 38 |
| THE NETWORKING EXCHANGE FOR EARLY CAREER PROFESSIONALS | 38 |
| SUNDAY • MAY 21 | 39 |
| SUNDAY MORNING | 39 |
| MEET THE EXPERT SEMINARS | 39 |
| K1: FRAN COMI KEYNOTE LECTURE | 39 |
| A1 CLINICAL YEAR IN REVIEW 1 | 39 |
| A2 JAMA AND THE NEW ENGLAND JOURNAL OF MEDICINE. DISCUSSION ON THE EDGE: REPORTS OF RECENTLY PUBLISHED CRITICAL CARE RESEARCH | 40 |
| A3 FELLOWS CASE CONFERENCE | 40 |
| A4 ACHIEVING HEALTH EQUITY IN GLOBAL CRITICAL CARE: CHALLENGES AND INNOVATIONS | 41 |
| A5 QUANTIFICATION OF ENVIRONMENTAL EXPOSURES USING STATE-OF-THE-ART METHODS | 41 |
| A6 BEYOND TRANSCRIPTOMICS: THE NEXT FRONTIER IN COPD/EMPHYSEMA | 42 |
| A7 THE NEW ATS CLINICAL PRACTICE GUIDELINES FOR PULMONARY REHABILITATION | 43 |
| A8 BRONCHOPULMONARY DYSPLASIA ACROSS THE LIFESPAN | 43 |
| A9 USING TECHNOLOGY TO SAVE THE BRAIN AND BODY: NOVEL INTERVENTIONS TO MANAGE PAIN, ANXIETY, DELIRIUM, AND PROMOTE MOBILITY IN ICU | 44 |
| A10 ASTHMA HOT TOPIC 2023: WHICH “ICS PLUS BRONCHODILATOR” RELIEVER FOR WHICH PATIENT? | 44 |
| A11 CARING FOR HISTORICALLY MARGINALIZED PATIENTS: ETHICAL, LEGAL AND ADVOCACY PRIMER FOR PROVIDERS | 45 |
| A12 PUBLICATION TO EMPOWERMENT- TRANSITIONING SCIENCE INTO ENVIRONMENTAL JUSTICE ADVOCACY | 46 |
| A13 ASTHMA, THE NEXT FRONTIER: NEW DEVELOPMENTS IN PATHOPHYSIOLOGY AND TREATMENT | 47 |
| A14 THIS IS GETTING COMPLICATED: EPIGENETICS, -OMICS, AND CELL SIGNALING IN PULMONARY HYPERTENSION | 47 |
| A15 TAKING PULMONARY REHABILITATION TO THE NEXT LEVEL | 48 |
| A16 INTERROGATING GENOMIC, TRANSCRIPTIONAL, AND EPIGENETIC MECHANISMS IN LUNG FIBROSIS | 48 |
| A17 TELL ME WHAT YOU SEE: NEW STUDIES IN LUNG IMAGING | 49 |
| A18 BREAKING NEWS IN OSA: NEW APPROACHES AND NEW TRIALS | 49 |
| A19 LUNG CANCER SCREENING: WHERE THE RUBBER MEETS THE ROAD | 50 |
| A21 INFECTION, LUNG INJURY, AND SEPSIS FROM MODELS TO TRANSLATION | 50 |
| A22 UNDERSTANDING THE IMPACT OF HEALTH DISPARITIES ON LUNG HEALTH | 51 |
| A23 LEVERAGING IMAGING AND BIOSAMPLES TO IMPROVE DIAGNOSIS AND RISK PREDICTION IN ILA AND ILD | 52 |
| A24 COPD PHENOTYPES: LOOKING OUTSIDE THE LUNG | 53 |
| A25 ‘OMICS AND THE EXPOSOME: HIGH DIMENSIONAL METHODS IN ENVIRONMENTAL LUNG HEALTH RESEARCH | 54 |
| A26 PRECISION-BASED APPROACHES TO PULMONARY VASCULAR DISEASE | 55 |
| A27 WHITE PLAGUE (TUBERCULOSIS) RESEARCH | 55 |
| A28 WHAT IS TRENDY IN THE PNEUMONIA WORLD? | 56 |
| A29 EPITHELIUM: FIRST LINE OF DEFENSE | 57 |
| A30 ALL THINGS INTERVENTIONAL PULMONARY A LIVELY POSTER DISCUSSION | 58 |
| A31 GLOBAL AND ENVIRONMENTAL INFLUENCES IN ASTHMA | 59 |
| A32 CASES IN AUTOIMMUNITY, AUTOINFLAMMATION, AND INFECTION | 61 |
| A33 LATE BREAKING ADVANCES IN ASTHMA AND IMMUNOLOGY | 62 |
| A34 IDENTIFYING AND IMPROVING PALLIATIVE CARE NEEDS ACROSS THE CARE CONTINUUM | 63 |
| A35 LEVERAGING USE OF INFORMATICS AND TECHNOLOGY | 63 |
| A36 SLEEP-RELATED HEALTH SERVICES RESEARCH | 64 |
| A37 CASE REPORTS: AUTOIMMUNITY, COVID, AND LUNG DISEASE, OH MY! | 65 |
| A38 ADVANCING OUR UNDERSTANDING AND TREATMENT OF ILD | 66 |
| A39 MANAGEMENT OF INTERSTITIAL LUNG DISEASE AND ITS CO-MORBIDITIES | 67 |
| A40 AIRWAY CASE REPORTS: HEMOPTYSIS, ANOMALIES, AND MORE | 68 |
| A41 EMERGING CLINICAL AND TRANSLATIONAL RESEARCH IN COPD AND ALPHA-1-ANTITRYPSIN | 69 |
| A42 CHRONIC COUGH: CUTTING EDGE CLINICAL STUDIES AND CASE REPORTS | 70 |
| A43 CLINICAL STUDIES IN INTERVENTIONAL PULMONARY AND PLEURAL DISEASE | 71 |
| A44 COVID AND ITS CONSEQUENCES: PART I | 71 |
| A45 ICU PRACTICES, QUALITY IMPROVEMENT, AND MEDICAL EDUCATION | 73 |
| A46 ECMO, ARDS, AND ACUTE RESPIRATORY FAILURE | 74 |
| A47 AUTOIMMUNITY, RHEUMATOLOGY, AND THERMOREGULATION: CASE REPORTS | 75 |
| A48 NEUROCRITICAL CARE CASE REPORTS | 76 |
| A49 CARDIAC AND VASCULAR CRITICAL CARE CASES | 77 |
| A50 CRITICAL CARE CASE REPORTS: CARDIAC AND VASCULAR DISEASE | 77 |
| A51 MANAGEMENT AND IMPACT OF THE COVID-19 PANDEMIC ON RESPIRATORY HEALTH | 78 |
| A52 STUDIES AND CASE REPORTS IN OCCUPATIONAL LUNG DISEASE | 79 |
| A53 CUTTING EDGE: ADVANCES IN PEDIATRIC TECHNOLOGY AND AIRWAY MONITORING | 80 |
| A54 PEDIATRIC PULMONARY VASCULAR DISEASE | 81 |
| A55 ZEBRAS FOR $800: RARE PEDIATRIC LUNG DISEASE CASES | 81 |
| A56 PEDIATRIC BRONCHIECTASIS CASES | 82 |
| A57 GREAT CASE! INTERESTING CASES IN PULMONARY VASCULAR DISEASE | 83 |
| A58 VISUALIZING THE FUTURE: IMAGING IN PULMONARY HYPERTENSION | 84 |
| A59 CLOTS, CLOTS, AND MORE CLOTS: VENOUS THROMBOEMBOLIC DISEASE | 85 |
| A60 LET’S MEET AT DUPONT CIRCLE: NEW MOLECULAR TRAFFIC PATTERNS IN PULMONARY HYPERTENSION | 86 |
| A61 TUBERCULOSIS | 86 |
| A62 B-A-C-T-E-R-I-A, FIND OUT WHAT IT MEANS TO ME | 88 |
| A63 NTM AND BRONCHIECTASIS, STILL TOGETHER | 89 |
| A64 POST-COVID19 REHABILITATION | 90 |
| A65 THE ALVEOLAR NICHE IN THE SPOTLIGHT OF LUNG FIBROSIS | 91 |
| A66 DISSECTING THE MATRIX AND MESENCHYMAL CELLS IN FIBROSIS | 92 |
| A67 BIOMARKERS, MEDIATORS, AND TRANSLATIONAL MODELS FOR ILD | 93 |
| A68 MITOCHONDRIAL AND METABOLOMIC ALTERATIONS IN THE PATHOGENESIS OF ILDs | 95 |
| A69 AN IMAGE’S WORTH: STUDIES IN LUNG IMAGING | 95 |
| A70 RELAX ALREADY! MECHANISTIC INSIGHTS INTO AIRWAY SMOOTH MUSCLE BIOLOGY | 97 |
| A71 MATTERS OF THE HEART...AND LUNGS: STUDIES ON CARDIOPULMONARY VASCULAR DISEASE | 98 |
| A72 NEW INSIGHTS INTO PAP EFFECTIVENESS | 98 |
| A73 DISPATCH FROM THE SLEEP LAB: UNCOVERING OSA PATHOPHYSIOLOGY | 99 |
| A74 RARE CASES IN THORACIC ONCOLOGY | 99 |
| A75 A MEDLEY OF INTERESTING LUNG CANCER CASES | 101 |
| ME101 BUILDING BLOCKS TO CRAFTING A SUCCESSFUL CLINICIAN-EDUCATOR CAREER | 102 |
| SECTION ON MEDICAL EDUCATION | 102 |
| SUNDAY MID-DAY | 103 |
| DIVERSITY FORUM | 103 |
| CC1 SLEEP CLINICAL CORE CURRICULUM | 103 |
| ASSEMBLY MEMBERSHIP MEETINGS | 103 |
| SPS1 THE AMERICAN THORACIC SOCIETY AND AMERICAN COLLEGE OF CHEST PHYSICIANS JOINT SESSION ON BRONCHIECTASIS | 104 |
| L1 OPPORTUNITIES IN SLEEP AND RESPIRATORY HEALTH DISPARITIES RESEARCH FUNDED BY NIMHD | 104 |
| L2 UPDATES FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION: TOOLS FOR CLINICIANS | 105 |
| L3 RECENT CLINICAL AND OMICS FINDINGS IN PATIENTS WITH PULMONARY HYPERTENSION FROM THE NHLBI PVDOMICS PROGRAM | 105 |
| L4 ADVANTAGES OF NASA SATELLITE DATA IN AIR QUALITY AND RESPIRATORY HEALTH APPLICATIONS | 106 |
| L5 CUTTING EDGE IN TRANSLATION - NHLBI CATALYZE PROGRAM | 106 |
| L6 COMMUNITY RESULTS FROM ASTHMA EMPOWERMENT COLLABORATIONS TO REDUCE CHILDHOOD ASTHMA DISPARITIES | 107 |
| MEET THE EXPERT SEMINARS | 107 |
| SUNDAY AFTERNOON | 108 |
| A81 PEDIATRIC YEAR IN REVIEW | 108 |
| A82 RACE AND PFTs: USE, CONTROVERSIES, AND ALTERNATIVES | 109 |
| A83 GREAT CASES: CLINICAL, RADIOLOGIC, AND PATHOLOGIC CORRELATIONS BY MASTER CLINICIANS | 109 |
| A84 NEW ENGLAND JOURNAL OF MEDICINE AND JAMA. DISCUSSION ON THE EDGE: REPORTS OF RECENTLY PUBLISHED PULMONARY RESEARCH | 110 |
| A85 PHYSIOLOGICAL AND CELLULAR IMPACT OF ENVIRONMENTAL EXPOSURES | 110 |
| A86 PHYSICAL FITNESS AND LUNG HEALTH | 111 |
| A87 NEW TREATMENT APPROACHES FOR BRONCHIECTASIS | 111 |
| A88 NEURO-IMMUNE INTERACTIONS IN LUNG DEVELOPMENT AND DISEASE | 112 |
| A89 CAN ENVIRONMENTAL INTERVENTIONS CHANGE THE SOCIAL DETERMINANTS OF HEALTH? | 112 |
| A90 MYTHS OR TRUTHS: CONTROVERSIES IN RESPIRATORY MEDICINE, THE NEW FRONTIER | 113 |
| A93 MECHANISTIC INSIGHTS AND NOVEL THERAPEUTICS IN ACUTE LUNG INJURY | 114 |
| A94 ADVANCES IN HEALTH SERVICES RESEARCH FOCUSED ON INTERSTITIAL LUNG DISEASE AND CYSTIC FIBROSIS | 114 |
| A95 THIS IS YOUR BRAIN ON (ICU) DRUGS: SEDATION, DELIRIUM, AND LONG-TERM COGNITIVE IMPAIRMENT | 115 |
| A96 ENHANCING SUPPORT FOR PATIENTS AND FAMILIES EXPERIENCING SERIOUS ILLNESS | 115 |
| A97 RISE OF THE MACHINES: -OMICS AND COMPUTATIONAL BIOLOGY IN PULMONARY HYPERTENSION | 116 |
| A98 HOST VS. BUG | 116 |
| A99 CLINICAL TRIALS IN CHRONIC LUNG DISEASE | 117 |
| A101 LINKING BIOLOGY TO THE REAL WORLD IN ASTHMA AND ALLERGIC INFLAMMATION | 117 |
| A102 THE DEVELOPMENT, PROGRESSION, AND TREATMENT OF ILD | 118 |
| A103 TOWARDS IMPROVING ICU PRACTICE | 119 |
| A104 NOVEL INSIGHTS ON CANNABIS, TOBACCO, AND E-CIGARETTE USE | 120 |
| A105 I NEED A HERO: PEDIATRIC INTERVENTIONAL BRONCHOSCOPY CASES | 121 |
| A106 MICROBIOME RESEARCH | 122 |
| A107 AGING AND LUNG DISEASES COMING TO AGE | 122 |
| A108 NEW INSIGHTS INTO CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 123 |
| A109 MICE TO HUMANS: MECHANISTIC DISCOVERIES IN SLEEP APNEA | 124 |
| A110 LUNG CANCER RISK, SCREENING, TREATMENT, AND OUTCOMES | 125 |
| SUNDAY AWARDS SESSSION | 126 |
| SECTION ON TERRORISM AND INHALATION DISASTERS | 127 |
| ASSEMBLY MEMBERSHIP MEETINGS | 127 |
| MONDAY • MAY 22 | 128 |
| MONDAY MORNING | 128 |
| MEET THE EXPERT SEMINARS | 128 |
| K2: KEYNOTE LECTURE | 128 |
| B1 CLINICAL YEAR IN REVIEW 2 | 128 |
| B2 PRO CON DEBATES ON PLEURAL CONTROVERSIES: WHAT PULMONOLOGISTS NEED TO KNOW | 129 |
| B3 TARGETING MUCUS ACROSS LUNG DISEASES: FROM PATHOGENESIS AND IMAGING TO THERAPY | 129 |
| B4 FAIL SMARTER AND LEARN FASTER: MOVING BEYOND BYSTANDER TRAINING TO ORGANIZATIONAL STRATEGIES TO REINFORCE THE DEI PIPELINE IN PULMONARY AND CRITICAL CARE | 130 |
| B5 BACK TO BASICS: HARNESSING THE POWER OF MOUSE MODELS TO UNDERSTAND HUMAN SEPSIS | 131 |
| B6 NON-PAP ALTERNATIVES FOR OSA: FROM ACCEPTED TO REVOLUTIONARY | 131 |
| B7 SICKLE CELL LUNG DISEASE ACROSS THE LIFESPAN: WHERE ARE WE NOW? | 132 |
| B8 BEYOND THE LUNGS: EXTRAPULMONARY MANIFESTATIONS OF PULMONARY VASCULAR DISEASE | 133 |
| B9 SEX-SPECIFIC MECHANISMS OF LUNG DISEASE PATHOGENESIS THROUGH THE LENS OF SINGLE CELL RNA SEQUENCING | 133 |
| B10 REIGNITING THE CANCER MOONSHOT: ATS = MISSION CONTROL FOR LUNG CANCER | 134 |
| B11 GLOBAL INSIGHTS ON THE LONG-TERM SEQUELAE OF INFECTIONS: BEYOND COVID | 135 |
| B12 ATS CLINICAL PRACTICE GUIDELINES: CLINICAL PRACTICE ON THE CUTTING EDGE | 135 |
| B13 BREAKING NEWS: CLINICAL TRIAL RESULTS IN PULMONARY MEDICINE | 136 |
| B14 COVID SEVERITY, OUTCOMES, AND DISPARITIES: FROM MOLECULE TO COMMUNITY | 136 |
| B15 ASTHMA: HOT OFF THE PRESS FROM THE BENCH TO THE CLINIC | 137 |
| B16 THE CURRENT STATE OF CRITICAL CARE: ROLE OF SYSTEMS AND HEALTH DISPARITIES | 137 |
| B17 EMERGING DATA ON DISEASE AND SYMPTOM BASED THERAPEUTICS FOR PATIENTS WITH IPF | 138 |
| B18 TIME TO ACT: INTERVENTIONS TO REDUCE RESPIRATORY HEALTH EFFECTS OF POLLUTANTS | 138 |
| B19 PLAYING THE TIKI-TAKA: THE CELL CROSSTALK GAME IN LUNG REPAIR | 139 |
| B20 THE ONLY CONSTANT IS CHANGE: NEW INSIGHTS INTO AIRWAY REMODELING | 139 |
| B21 SUPPORTING PATIENTS AND FAMILIES THROUGH SERIOUS ILLNESS AND RECOVERY | 140 |
| B22 NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1 | 141 |
| B23 ADVANCING THE SCIENCE OF ACUTE RESPIRATORY FAILURE | 142 |
| B24 NOT YET OUT OF THE WOODS: LONG-TERM OUTCOMES AFTER THE ICU | 143 |
| B25 TOP HEMATOLOGY/ONCOLOGY CRITICAL CARE CASE REPORTS | 143 |
| B26 IT’S TIME TO ADVANCE THE CARE OF PATIENTS WITH COPD, PULMONARY HYPERTENSION, AND OTHER LUNG CONDITIONS | 144 |
| B27 EVOLVING CONCEPTS IN LUNG FUNCTION TESTING AND MONITORING | 145 |
| B28 SOLVING THE PUZZLE OF BRONCHIECTASIS AND NONTUBERCULOUS MYCOBACTERIA | 145 |
| B29 EXCITING DEVELOPMENTS IN PULMONARY REHABILITATION | 146 |
| B30 BREATHE (IN THE AIR): STUDIES IN PULMONARY FUNCTION | 147 |
| B31 ASTHMA: FROM MICE TO MEN, AND BACK AGAIN | 148 |
| B32 WHEEZES, HIVES, AND THERAPIES GONE AWRY | 149 |
| B33 TOPICS IN QUALITY IMPROVEMENT AND IMPLEMENTATION SCIENCE | 150 |
| B34 HEALTH SERVICES AND EPIDEMIOLOGY RESEARCH IN OBSTRUCTIVE LUNG DISEASE | 152 |
| B35 IMPROVING MEDICAL EDUCATION IN PULMONARY, CRITICAL CARE, AND SLEEP | 153 |
| B36 THE GOOD, THE BAD, AND THE UGLY: DRUG TOXICITY CASE REPORTS | 153 |
| B37 ILD CASE REPORTS: THE SPECTRUM FROM DIAGNOSIS TO TREATMENT | 155 |
| B38 SARCOID IS ALWAYS IN THE DIFFERENTIAL: CASE REPORTS IN SARCOIDOSIS | 156 |
| B39 ADVANCES IN LUNG TRANSPLANTATION | 157 |
| B40 POTPOURRI IN ILD: SPANNING THE SPECTRUM FROM RARE TO COMMON LUNG DISEASES | 157 |
| B41 RISK FACTORS AND OUTCOMES FOR COPD EXACERBATIONS | 158 |
| B42 DIAGNOSTIC TESTING AND CASE REPORTS IN DYSPNEA AND LUNG DISEASE | 159 |
| B43 UNCOMMON TYPES AND CAUSES OF PLEURAL EFFUSION: CASE REPORTS IN PLEURAL DISEASE | 160 |
| B44 FRAILTY, NUTRITION, AND PROLONGED MECHANICAL VENTILATION | 161 |
| B45 NEW STUDIES IN SEPSIS AND INFECTIOUS DISEASES | 162 |
| B46 OTHER SPECIALTIES IN THE ICU: TOPICS IN NEPHROLOGY, HEMATOLOGY/ONCOLOGY, AND MORE | 163 |
| B47 CRITICAL CARE NEPHROLOGY: CASE REPORTS | 164 |
| B48 TOXICOLOGY AND OTHER MEDICATIONS IN THE ICU: CASE REPORTS | 165 |
| B49 CASE REPORTS IN NEUROCRITICAL CARE | 166 |
| B50 CASES IN PULMONARY CRITICAL CARE | 166 |
| B51 ENVIRONMENTAL AND CLINICAL EPIDEMIOLOGY OF AIRWAY DISEASE, ASTHMA, AND COPD | 167 |
| B52 MECHANISMS OF PULMONARY TOXICITY | 168 |
| B53 PEDIATRIC ASTHMA BENCH TO BEDSIDE | 168 |
| B54 EARLY ORIGINS OF PEDIATRIC LUNG DISEASE | 170 |
| B55 GETTING TO THE HEART OF CARDIOPULMONARY ANOMALIES AND DIAGNOSTIC DILEMMAS IN PH | 171 |
| B56 -OMICS, MACHINES, AND DEVICES IN PULMONARY HYPERTENSION | 172 |
| B57 INTERMEDIATES, CORRELATES, AND SURROGATES, OH MY!: NOVEL END POINTS AND ASSESSMENTS IN PVD | 173 |
| B58 DON’T FORGET ABOUT THE BLOOD VESSELS! PULMONARY VASCULAR FUNCTION IN ACUTE LUNG INJURY | 174 |
| B59 BREAKING BAD: NEW DRUGS AND FORMULATIONS FOR PULMONARY HYPERTENSION AND RV FAILURE | 174 |
| B60 LIFE MOVES FAST! LATE BREAKERS IN PULMONARY HYPERTENSION | 175 |
| B61 MORE OF COVID-19 | 176 |
| B62 FUNGI EVERYWHERE! | 177 |
| B63 IMMUNOCOMPROMISED HOST PROBLEMS AND COMPLICATIONS | 178 |
| B64 THE MULTIPLE COMPONENTS OF PULMONARY REHABILITATION | 179 |
| B65 IMMUNE AND ENDOTHELIAL CELLS HIT BACK AT LUNG REPAIR | 180 |
| B66 BUG’S LIFE: FROM PNEUMONIA TO SEPSIS | 181 |
| B67 ALL THE LUNG’S A STAGE: IMMUNE CELLS ARE THE PLAYERS | 182 |
| B68 A DIFFERENT POINT OF VIEW: LUNG IMAGING IN COPD | 183 |
| B69 AIRWAY INJURY AND REPAIR: MECHANISMS AND TREATMENT | 184 |
| B70 INHALE THE FUTURE: NEW FINDINGS IN PULMONARY FUNCTION | 185 |
| B71 BEYOND CPAP: THERAPIES FOR SLEEP APNEA | 186 |
| B72 EXCITING CASES IN INTERVENTIONAL PULMONARY AND PLEURAL DISEASE | 187 |
| B73 TRULY SYMPTOMATIC OR JUST MIMICKING? LUNG CANCER CASES | 188 |
| ME102 DISCUSSING AND TEACHING ABOUT HEALTHCARE DISPARITIES | 189 |
| MONDAY MID-DAY | 190 |
| ATS WOMEN’S FORUM | 190 |
| SECTION ON GENETICS AND GENOMICSMEMBERSHIP MEETING | 190 |
| SPS2 ATS ADVANCING ADULT IMMUNIZATION INITIATIVE: IMMUNE BOOST! ADDRESSING VACCINE HESITANCY AND THE LANDSCAPE OF VACCINE-PREVENTABLE DISEASES | 190 |
| CC2 CRITICAL CARE CLINICAL CORE CURRICULUM | 191 |
| PCC1 PEDIATRIC CLINICAL CORE CURRICULUM | 191 |
| L7 CIRCADIAN RHYTHMS IN PULMONARY AND CRITICAL CARE: IMPLICATIONS FOR HEALTH AND DISEASE | 192 |
| L8 PURSUING THE RIGHT FUNDING SOURCE: INSTITUTES, ORGANIZATIONS AND FOUNDATIONS SHARE THEIR FUNDING PRIORITIES | 192 |
| L9 GENERIC DRUG DEVELOPMENT FOR RESPIRATORY PRODUCTS, US FOOD AND DRUG ADMINISTRATION UPDATE | 193 |
| L10 NEW FINDINGS ON ASTHMA AND ALLERGIC DISEASE IN URBAN ENVIRONMENTS | 193 |
| L11 DISPARITIES IN WORK-RELATED RESPIRATORY DISEASE | 194 |
| L12 THE MOLECULAR ATLAS OF LUNG DEVELOPMENT (LUNGMAP), PHASE 2 | 194 |
| L13 GENOMICS ANALYSES FROM MILLION VETERAN PROGRAM IMPROVE LUNG CANCER DETECTION AND CARE | 195 |
| L14 UPDATE ON PRECLINICAL MODELS OF IPF - AN NHLBI CONSORTIUM | 195 |
| MEET THE EXPERT SEMINARS | 196 |
| MONDAY AFTERNOON | 196 |
| PRESENTATION OF THE RECOGNITION AWARDSFOR SCIENTIFIC ACCOMPLISHMENTS | 196 |
| CC3 SLEEP CLINICAL CORE CURRICULUM | 197 |
| B81 NURSING YEAR IN REVIEW - WE CAN’T WAIT: ASSURING A PULMONARY, CRITICAL CARE, AND SLEEP NURSING WORKFORCE | 197 |
| B82 THE GENETICS OF INTERSTITIAL LUNG DISEASE: CURRENT STATE AND FUTURE PROMISE | 198 |
| B83 WHY YES, YOU CAN SKI WITH YOUR VENTILATOR! USING TECHNOLOGY TO KEEP NIV/IMV VENTILATOR DEPENDENT PATIENTS ACTIVE AND ENGAGED IN THEIR COMMUNITIES | 198 |
| B84 NEXT GENERATION CRITICAL CARE TRIALS: FROM PRAGMATIC TRIALS TO PRECISION MEDICINE | 199 |
| B85 PROCESSING THE ENVIRONMENT: LUNG LYMPHATICS AND FOLLICLES IN DISEASE | 199 |
| B86 PRECISION MEDICINE IN PNEUMONIA | 200 |
| B87 CONTROVERSIES IN PEDIATRIC OBSTRUCTIVE SLEEP APNEA: A PRO/CON DEBATE | 201 |
| B88 LEAPS AND BOUNDS: REDUCING HEALTHCARE’S CARBON FOOTPRINT | 201 |
| B89 TRANSCRIPTOMIC PROFILING OF PULMONARY VASCULAR LESIONS UNRAVEL MECHANISMS OF PULMONARY ARTERIAL HYPERTENSION | 202 |
| B90 IMPROVING THE DIAGNOSIS AND MANAGEMENT OF PEDIATRIC ACUTE RESPIRATORY DISTRESS SYNDROME | 203 |
| B91 LUNG AGING: WHY YOUR FEV1 IS FALLING AND PNEUMONIA IS YOUR FINAL FRIEND | 203 |
| B92 INNOVATIVE APPROACHES TO PERSONALIZED SEVERE ASTHMA MANAGEMENT | 204 |
| B93 BREAKTHROUGHS IN ILD: TRANSLATION TO THE BEDSIDE | 204 |
| B94 DISEASE PROGRESSION AND MORBIDITY ALONG THE SPECTRUM OF COPD: FROM EARLY TO ESTABLISHED | 205 |
| B95 TOWARDS IMPROVING ICU AND POST-ICU OUTCOMES | 205 |
| B96 BEST IN PEDIATRICS | 206 |
| B97 RISKY BUSINESS: TREATMENTS AND CLINICAL TARGETS IN PULMONARY HYPERTENSION | 206 |
| B98 THE HAPPY COUPLE: BRONCHIECTASIS AND NONTUBERCULOUS MYCOBACTERIA | 207 |
| B99 ALL THAT WHEEZES: TRANSLATIONAL STUDIES IN ASTHMA | 207 |
| B101 OMICS STUDIES OF IMMUNE CELLS AND THE LUNG | 208 |
| B102 ADVANCES IN MEDICAL EDUCATION IN PULMONARY, CRITICAL CARE, AND SLEEP MEDICINE | 209 |
| B103 HOT TOPICS IN CYSTIC FIBROSIS, BRONCHIECTASIS, AND BREATHLESSNESS | 210 |
| B104 TOP CASE REPORTS OF MECHANICAL VENTILATION/ARDS FROM THE PAST YEAR | 211 |
| B105 SICK ON THE JOB: UNCOVERING MODERN OCCUPATIONAL HAZARDS | 212 |
| B106 FROM ACUTE TO LONG COVID-19 | 212 |
| B107 COPD: FROM OMICS TO TREATMENT | 213 |
| B108 IMMUNE CELLS TO THE RESCUE IN LUNG INJURY | 214 |
| B109 BIOMARKERS, GENETICS, AND OMICS IN SLEEP DISORDERED BREATHING | 215 |
| B110 PROBING THE LUNG: THE LATEST IN INTERVENTIONAL PULMONARY | 216 |
| ASSEMBLY MEMBERSHIP MEETINGS | 217 |
| TUESDAY • MAY 23 | 218 |
| TUESDAY MORNING | 218 |
| MEET THE EXPERT SEMINARS | 218 |
| K3: KEYNOTE LECTURE | 218 |
| C1 CLINICAL YEAR IN REVIEW 3 | 218 |
| C2 ENDPOINTS FOR THERAPEUTIC TRIALS IN ILD | 219 |
| C3 PEDIATRIC CLINICAL CHEST ROUNDS | 219 |
| C4 FLUID AND VASOPRESSOR RESUSCITATION FOR EARLY SEPSIS: WHEN, WHICH, AND HOW MUCH? | 220 |
| C5 DISMANTLING STRUCTURAL RACISM FROM RISK AND DISEASE PREDICTION IN PULMONARY AND CRITICAL CARE MEDICINE | 220 |
| C6 DISPARITIES IN RESPIRATORY GENOMICS RESEARCH: STRATEGIES TO ADVANCE SCIENCE AND CLINICAL CARE | 221 |
| C7 CANCER IN THOSE WHO HAVE NEVER SMOKED: NEW INSIGHTS FROM BENCH TO BEDSIDE | 222 |
| C8 NEW CONCEPTS AND UPDATE IN THE DIAGNOSIS AND MANAGEMENT OF NTM AND TB INFECTIONS | 222 |
| C9 REHABILITATION FOR THE POST-COVID POPULATION | 223 |
| C10 OPIOID USE DISORDER, SLEEP DEFICIENCY, AND VENTILATORY CONTROL: BIDIRECTIONAL MECHANISMS AND THERAPEUTIC TARGETS | 224 |
| C11 ADVANCING CLINICAL ISSUES TO ATS AND CAPITOL HILL: THE OXYGEN THERAPY EXEMPLAR | 224 |
| C12 IMMUNOLOGY IN CONTEXT: MECHANISMS AND BIOMARKERS THAT DETERMINE VIRAL DISEASE SEVERITY | 225 |
| C13 CYTOKINES: CYTOKINES IN THE AIRWAYS | 226 |
| C14 SOCIAL DETERMINANTS OF HEALTH AND TREATMENT OF ASTHMA | 226 |
| C15 EMERGING COPD DIAGNOSTICS AND TREATMENTS | 227 |
| C16 THE ROAD TO RECOVERY: IMPROVING LONG-TERM OUTCOMES AFTER CRITICAL ILLNESS | 227 |
| C17 IN THIS TOGETHER: CONFRONTING ENVIRONMENTAL HEALTH CHALLENGES AROUND THE WORLD | 228 |
| C18 BOSS BABY: EMERGING PRINCIPLES IN BPD AND LUNG DEVELOPMENT | 228 |
| C19 EMERGING MECHANISMS IN COPD AND ASTHMA | 229 |
| C21 “CUTTING” EDGE: CLINICAL STUDIES IN INTERVENTIONAL PULMONARY AND PLEURAL DISEASE | 229 |
| C22 CLINICAL AND TRANSLATIONAL STUDIES IN MECHANICAL VENTILATION | 230 |
| C23 BUILDING THE FUTURE OF CRITICAL CARE: STUDIES IN MEDICAL EDUCATION | 231 |
| C24 DISPARITIES IN THE HEALTH EFFECTS OF CLIMATE CHANGE AND POLLUTANTS | 232 |
| C25 OPPORTUNITIES AND ADVANCES IN PEDIATRIC GLOBAL HEALTH | 233 |
| C26 UNRAVELING THE GORDIAN KNOT: MULTI-DIMENSIONAL -OMICs AND SIGNALING MOTIFS IN PULMONARY VASCULAR DISEASE | 234 |
| C27 OPTIMIZING THE INTERVENTIONS AND PROGRAM MODELS OF PULMONARY REHABILITATION | 235 |
| C28 FROM OMICS TO EX VIVO MODELS: A ROAD MAP FOR NOVEL THERAPIES IN LUNG FIBROSIS | 235 |
| C29 MORE THAN MEETS THE EYE: ADVANCED LUNG IMAGING | 236 |
| C30 LUNG CANCER SURGERY APPROACHES AND OUTCOMES | 237 |
| C31 BIOLOGICS WANT TO RULE THE (ASTHMA) WORLD | 238 |
| C32 THE AIRWAY BATTLE FOR DOMINANCE: IMMUNE SYSTEM VERSUS INFECTIONS | 239 |
| C33 ADVANCES AND UNSOLVED MYSTERIES IN COPD | 240 |
| C34 SARCOIDOSIS, FIBROSIS, AND PROTEINOSIS - OH MY! | 240 |
| C35 HEALTH SERVICES AND EPIDEMIOLOGY RESEARCH IN HOSPITALIZED AND CRITICALLY ILL POPULATIONS | 241 |
| C36 HIGHLIGHTS IN BEHAVIORAL SCIENCES AND HEALTH SERVICES RESEARCH | 242 |
| C37 ONGOING IMPACT OF THE COVID-19 PANDEMIC | 243 |
| C38 CASE REPORTS IN RARE LUNG DISEASE: FIND YOUR ZEBRAS HERE | 244 |
| C39 CARE AND EVALUATION OF PATIENTS WITH INTERSTITIAL LUNG DISEASE | 246 |
| C40 CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD | 247 |
| C41 A “PLEUR”ALITY OF ISSUES: CASE REPORTS IN PLEURAL DISEASE DIAGNOSTICS AND MANAGEMENT | 248 |
| C42 ZEBRAS AND PEANUTS: FOREIGN BODIES AND RARE CASES FROM IP AND PLEURAL DISEASE | 249 |
| C43 THERAPEUTIC MISADVENTURES: PROCEDURAL COMPLICATIONS ENCOUNTERED IN INTERVENTIONAL PULMONARY AND PLEURAL DISEASE | 250 |
| C44 NOVEL TECHNIQUES AND PROCEDURAL INNOVATIONS IN INTERVENTIONAL PULMONARY AND PLEURAL DISEASE | 250 |
| C45 COVID AND ITS CONSEQUENCES: PART II | 251 |
| C46 STUDIES IN CARDIAC ARREST, ICU PHARMACY, AND ALCOHOL WITHDRAWAL | 253 |
| C47 ORGAN FAILURES AND SHOCK: CASE REPORTS | 253 |
| C48 CASE REPORTS: TOXICOLOGY AND OTHER INVOLVING MEDICATIONS | 254 |
| C49 HEMATOLOGY/ONCOLOGY CRITICAL CARE CASES | 255 |
| C50 ALL THAT IS HLH | 256 |
| C51 CASES OF COVID AND ITS COMPLICATIONS | 256 |
| C52 ENDOCRINOLOGY IN THE ICU: CASE REPORTS | 257 |
| C53 CRITICAL CARE GASTROENTEROLOGY: CASES | 258 |
| C54 CASES OF INFECTIOUS DISEASES IN THE ICU - I | 259 |
| C55 CASES OF INFECTIOUS DISEASES IN THE ICU - II | 260 |
| C56 TRENDS AND PREDICTORS OF RESPIRATORY HEALTH AROUND THE WORLD | 261 |
| C57 CASE REPORTS IN PULMONARY AND ENVIRONMENTAL HEALTH | 262 |
| C58 HEALTH SERVICES RESEARCH IN DIVERSE SETTINGS | 263 |
| C59 CELLULAR DYSFUNCTION: PEDIATRIC CANCER, IMMUNODEFICIENCY, AND UNUSUAL INFECTIONS | 263 |
| C60 CHILDHOOD INTERSTITIAL LUNG DISEASE (chILD) | 264 |
| C61 CLINICAL CASES IN PEDIATRIC SLEEP | 264 |
| C62 CANCER, CLOTS, AND OTHER PULMONARY VASCULAR OBSTRUCTIONS | 265 |
| C63 THINKING OUTSIDE THE BOX: NEW INSIGHTS INTO SUBGROUPS OF PULMONARY HYPERTENSION | 266 |
| C64 EXPANDING THE VENN DIAGRAM: COVID-19 AND THE PULMONARY VASCULATURE | 267 |
| C65 A LOT OF FUNGI! | 267 |
| C66 VIRAL INFECTIONS, COVID, AND BEYOND | 268 |
| C67 DON’T FORGET ABOUT THESE UNUSUAL LUNG INFECTIONS | 270 |
| C68 TOPICS IN AIRWAY AND ALVEOLAR EPITHELIAL CELL BIOLOGY | 271 |
| C69 PRECLINICAL COPD MODELS: IN VITRO, EX VIVO, IN VIVO | 272 |
| C70 COPD (AND LUNG CANCER) CLINICAL AND TRANSLATIONAL STUDIES | 273 |
| C71 NEW INSIGHTS IN BRONCHOPULMONARY DYSPLASIA | 274 |
| C72 HOUSE OF ARDS...AND MECHANICAL VENTILATORY SUPPORT | 275 |
| C73 CHEST DISEASE CLINICAL CASES | 275 |
| C74 DO NOT MISS: SLEEP DISORDERS IN VULNERABLE POPULATIONS | 277 |
| C75 SLEEP GEMS: CASE REPORTS FROM THE WORLD OF SLEEP MEDICINE | 277 |
| C76 SARCOMA AND NEUROENDOCRINE TUMORS: CASES IN THORACIC ONCOLOGY | 278 |
| C77 LUNG NODULES, CAVITIES, AND LYMPHOMAS: CASES IN THORACIC ONCOLOGY | 279 |
| ME103 GAME ON!: GAMIFICATION OF MEDICAL EDUCATION IN PCCM | 280 |
| SPS3 RESEARCH INTEGRITY IN MEDICAL EDUCATION: LESSONS FROM THE TUSKEGEE EXPERIMENT | 280 |
| PCC2 PEDIATRIC CLINICAL CORE CURRICULUM | 281 |
| TUESDAY MID-DAY | 281 |
| PLENARY SESSION | 281 |
| L15 NIH ENVIRONMENTAL INFLUENCES ON CHILD HEALTH OUTCOMES (ECHO): NATIONAL LONGITUDINAL RESOURCE FOR CHILD LUNG HEALTH RESEARCHERS | 282 |
| L16 IMPACT OF SEX AND GENDER ON AUTOIMMUNE LUNG DISEASE | 282 |
| L17 ENVIRONMENTAL HEALTH EQUITY UNDER THE RUBRIC OF VITAL CONDITIONS | 283 |
| L18 VA’S APPROACH TO POST-DEPLOYMENT RESPIRATORY HEALTH: RESEARCH, CLINICAL CARE AND EDUCATION | 283 |
| L19 NHLBI PREVENTION AND EARLY TREATMENT OF ACUTE LUNG INJURY (PETAL) NETWORK | 284 |
| L20 SYSTEMS BIOLOGY FOR ACUTE RESPIRATORY INFECTIONS | 284 |
| L21 NEW FINDINGS FROM THE SUBPOPULATIONS AND INTERMEDIATE OUTCOME MEASURES IN COPD II (SPIROMICS II) STUDY | 284 |
| MEET THE EXPERT SEMINARS | 285 |
| TUESDAY AFTERNOON | 286 |
| CC4 CRITICAL CARE CLINICAL CORE CURRICULUM | 286 |
| C82 BEYOND THE LUNG: ADDRESSING COMORBIDITIES IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 286 |
| C83 PRO/CON: HOT TOPICS IN INTERSTITIAL LUNG DISEASE | 287 |
| C84 CARDIAC ARREST: NEW SCIENCE AND CHANGING GUIDELINES | 287 |
| C85 A PATH TOWARDS A MORE DIVERSE AND INCLUSIVE WORKFORCE | 288 |
| C86 BEYOND THE TRANSCRIPTOME: HOW THE MULTI-“OMIC” UNIVERSE PROVIDES NOVEL INSIGHTS INTO IPF/ILD PATHOGENESIS | 289 |
| C87 A MEASURED RESPONSE: ASSESSING TREATMENT OUTCOMES IN PULMONARY HYPERTENSION | 289 |
| C88 BIOLOGICAL IMPACT OF COVID-19 ACROSS THE LIFESPAN | 290 |
| C89 ACHIEVING HEALTH EQUITY: REDUCING THE IMPACT OF SDOH THROUGH RESEARCH AND ADVOCACY | 290 |
| C90 DOUBLE TROUBLE: AIR POLLUTANTS AND TUBERCULOSIS | 291 |
| C91 THE E-CIGARETTE AND VAPING PRODUCT EPIDEMIC: IT'S IN THE JUICE | 292 |
| C92 ATS PRESIDENT'S SYMPOSIUM: EARLY LIFE DETERMINANTS (ANTECEDENTS) OF ADULT LUNG DISEASE | 292 |
| C93 DISPARITIES, TREATMENTS, AND OUTCOMES IN COPD | 293 |
| C94 CLINICAL AND TRANSLATIONAL STUDIES IN SEPSIS | 293 |
| C95 NOT JUST GENES: ENVIRONMENTAL EXPOSURES AND INTERSTITIAL LUNG DISEASE | 294 |
| C96 THE SCIENCE AND CLINICAL PRACTICE OF PULMONARY REHABILITATION | 294 |
| C97 EPITHELIAL RESPONSES TO LUNG INJURY | 295 |
| C98 RISKY BUSINESS: PREDICTING CONSEQUENCES OF OSA | 295 |
| C99 ADVANCES IN BIOMARKERS ACROSS THE LUNG CANCER CONTINUUM | 296 |
| C101 IMPACT OF BIOLOGICS ON ASTHMA OUTCOMES | 296 |
| C102 ASTHMA AND COPD: ADVANCING BEHAVIORAL SCIENCES AND HEALTH SERVICES RESEARCH | 297 |
| C103 MOVING THE NEEDLE FORWARD IN LUNG TRANSPLANTATION | 298 |
| C104 CLINICAL AND TRANSLATIONAL STUDIES IN ALI AND ARDS | 299 |
| C105 INFECTIONS IN THE ICU: THE BEST OF THE BEST CASES | 300 |
| C106 OUT OF THE ‘MUC’: UPDATES IN PCD AND CF | 301 |
| C107 AT THE CROSSROADS OF DISEASE: METABOLIC AND INFLAMMATORY DRIVERS IN PULMONARY VASCULAR DISEASE | 302 |
| C108 IMMUNITY AND INFLAMMATION IN COPD: NOVEL FINDINGS | 303 |
| C109 EVEN BETTER THAN THE REAL THING: ADVANCED MODELS OF LUNG DISEASE | 303 |
| C110 ADVANCED SIGNAL ANALYSIS: NEW DIAGNOSTICS AND PHYSIOLOGIC INSIGHTS FOR SDB | 304 |
| WEDNESDAY • MAY 24 | 306 |
| WEDNESDAY MORNING | 306 |
| MEET THE EXPERT SEMINARS | 306 |
| D1 CLINICAL YEAR IN REVIEW 4 | 306 |
| D2 COUGH IN PULMONARY FIBROSIS - ANNOYING SYMPTOM OR DRIVER/MARKER OF DISEASE PROGRESSION? | 307 |
| D3 IMAGING BIOMARKERS OF DISEASE MODIFICATION IN COPD | 307 |
| D4 THE LONG AND WINDING ROAD: THE FUTURE OF ICU OUTCOMES RESEARCH | 308 |
| D5 REVISITING BEST BUY INTERVENTIONS FOR THE DIAGNOSIS AND MANAGEMENT OF CHRONIC RESPIRATORY DISEASES IN LOW- AND MIDDLE-INCOME COUNTRIES | 308 |
| D6 OBESITY-RELATED ASTHMA: MECHANISTIC STUDIES BEGIN TO INFORM THERAPEUTICS | 309 |
| D7 WANT TO BE AN ADVOCATE FOR LUNG HEALTH? LEARN FROM SUCCESS! | 310 |
| D8 UNDER THE MAGNIFYING GLASS: OMICS AND DEEP PHENOTYPING IN PULMONARY VASCULAR DISEASES | 310 |
| D9 IT’S ABOUT TIME! THE CIRCADIAN CLOCK IN LUNG DISEASE, FROM BENCH TO BEDSIDE | 311 |
| D10 AN AGE-FRIENDLY FRAMEWORK FOR CARING FOR OLDER ADULTS WITH CHRONIC LUNG DISEASE | 311 |
| D11 THE EVOLVING ROLE FOR IMMUNOTHERAPY IN LUNG CANCER | 312 |
| D12 THE POST-COVID VIRAL SURGE: HOW DID VIRAL EXPOSURES, OR LACK THEREOF, INFLUENCE PEDIATRIC AND ADULT IMMUNITY? | 313 |
| D13 INNATE AND ADAPTIVE IMMUNE MECHANISMS REGULATING LUNG DISEASE | 313 |
| D14 CUTTING EDGE CONCEPTS IN BEHAVIORAL SCIENCES AND HEALTH SERVICES RESEARCH | 314 |
| D15 OUTCOMES IN SARCOIDOSIS | 314 |
| D16 ADVANCING THE SCIENCE OF ARDS AND ACUTE RESPIRATORY FAILURE | 315 |
| D17 BUGS, LUNGS, AND THE ENVIRONMENT: THE INTERPLAY BETWEEN AMBIENT EXPOSURES, MICROBIOME, AND RESPIRATORY INFECTION | 315 |
| D18 MOLECULAR TRAFFIC HUBS IN PULMONARY VASCULAR DISEASE | 316 |
| D19 NEW PERSPECTIVES ON TRANSLATIONAL STUDIES FOR LUNG FIBROSIS | 316 |
| D20 MECHANISTIC INSIGHTS IN SLEEP DISORDERED BREATHING | 317 |
| D21 TRANSLATIONAL COVID-19 STUDIES | 317 |
| D22 HOT TOPICS IN BEHAVIORAL SCIENCES AND HEALTH SERVICES RESEARCH | 318 |
| D23 DIAGNOSTIC DILEMMAS: CASE REPORTS IN INTERSTITIAL LUNG DISEASE AND LUNG TRANSPLANTATION | 319 |
| D24 ADVENTURES IN “PROCEDURE-ING”: CASE REPORTS IN INTERVENTIONAL PULMONARY AND PLEURAL DISEASE | 320 |
| D25 TOPICS IN SEPSIS AND SEPTIC SHOCK | 321 |
| D26 RISK FACTORS FOR COPD AND LUNG CANCER: BEYOND TOBACCO | 322 |
| D27 IMPROVING PEDIATRIC PULMONOLOGY CARE: BEHAVIORAL AND HEALTH SERVICES RESEARCH | 323 |
| D28 HOW CAN WE DO BETTER: EMERGING DIAGNOSTICS AND THERAPEUTICS IN PULMONARY VASCULAR DISEASE | 324 |
| D29 TRANSLATIONAL RESEARCH IN IPF | 325 |
| D30 INTEGRATING OSA AND COMORBIDITIES FOR EFFECTIVE THERAPIES | 326 |
| D31 IMAGING, BIOMARKERS, AND MACHINE LEARNING IN LUNG CANCER | 327 |
| WEDNESDAY MID-DAY | 328 |
| CC5 PULMONARY CLINICAL CORE CURRICULUM | 328 |
| L22 THE NHLBI LUNG TRANSPLANT CONSORTIUM | 328 |
| L23 INFLAMMATION RESOLUTION PATHWAYS IN ENVIRONMENTAL PULMONARY HEALTH AND MORBIDITY | 329 |
| L24 STUDY UPDATES FROM THE AMERICAN LUNG ASSOCIATION’S AIRWAY CLINICAL RESEARCH CENTERS NETWORK | 329 |
| L25 ELAFIN: FROM TRANSLATIONAL PPG TO CLINICAL TRIAL | 330 |
| L26 PULMONARY UPDATE FROM THE US FOOD AND DRUG ADMINISTRATION | 330 |
| L27 AIRWAY OMICS FOR DISEASE ENDOTYPING AND MANAGEMENT | 331 |
| L28 COPDGENE: ADVANCES IN COPD HETEROGENEITY AND PROGRESSION | 331 |
| MEET THE EXPERT SEMINARS | 332 |
| PCC3 PEDIATRIC CLINICAL CORE CURRICULUM | 332 |
| WEDNESDAY AFTERNOON | 333 |
| CC6 PULMONARY CLINICAL CORE CURRICULUM | 333 |
| D82 REPURPOSING EXISTING MEDICATIONS FOR TREATMENT OF COPD | 333 |
| D83 ESTABLISHING A PARADIGM FOR MULTIDISCIPLINARY CARE IN SARCOIDOSIS | 334 |
| D84 FROM GENES TO CLINICAL TRIALS: STATE-OF-THE-ART APPROACHES TO HETEROGENEITY IN THE ICU | 334 |
| D85 EARLY LIFE ENVIRONMENTAL EXPOSURES, EPIGENETICS, AND ASTHMA DEVELOPMENT | 335 |
| D86 HUMANS, ANIMALS, THE ENVIRONMENT: WHY IS THE ONE HEALTH APPROACH NEEDED FOR EMERGING HEALTH ISSUES? | 335 |
| D87 THE UN HIGH LEVEL MEETING ON TB 2023: A CHANCE TO BEAT THIS PARTICULAR PANDEMIC | 336 |
| D88 BEYOND BIOENERGETICS: CELLULAR METABOLISM IN LUNG HEALTH AND DISEASE | 337 |
| D89 OSA-ASSOCIATED INFLAMMATION AND COMORBIDITIES: CAUSES AND CONSEQUENCES | 337 |
| D91 LOOKING FOR THE CRYSTAL BALL: BIOMARKERS TO PREDICT DISEASE PROGRESSION AND MORTALITY IN ILD | 338 |
| D92 NOVEL IMAGING AND PHYSIOLOGIC MEASURES IN COPD | 338 |
| D93 CLINICAL AND TRANSLATIONAL STUDIES OF COVID-19 CRITICAL ILLNESS | 339 |
| D94 NOVEL REGULATORS AND MEDIATORS OF AIRWAY INFECTION AND INFLAMMATION | 339 |
| D95 CHALLENGES AND ADVANCES IN COVID-19 | 340 |
| D96 NOVEL PATHWAYS IN INFLAMMATORY LUNG INJURY | 340 |
| D97 IMPACT OF COPD ACROSS THE LIFESPAN | 341 |
| D98 UPDATE ON THE “OMICS” OF LUNG CANCER: A TRANSLATIONAL SESSION | 341 |
| D101 HOST DEFENSES AND IMMUNE CELLS | 342 |
| D102 HIGHLIGHTS OF EPIDEMIOLOGIC AND CLINICAL RESEARCH IN BEHAVIORAL SCIENCES | 343 |
| D103 THE DOUBLE EDGED SWORD: DRUG TOXICITY CASE REPORTS | 344 |
| D104 CARDIAC AND VASCULAR CRITICAL CARE: THE BEST CASE REPORTS FROM 2022 | 344 |
| D105 OVERCOMING OBSTACLES: APPROACHES TO PEDIATRIC SLEEP SCREENING AND TREATMENT | 345 |
| D106 HOT OFF THE PRESSES! LATE BREAKERS IN PULMONARY VASCULAR DISEASE | 346 |
| D107 ADVANCING THE SCIENCE IN VIRAL INFECTIONS | 347 |
| D108 CELLS, SIGNALING, AND MEDIATORS IN LUNG REMODELING AND FIBROSIS | 348 |
| D109 THE LONG AND THE SHORT OF LONG COVID | 349 |
| Back Cover | 350 |